DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Harreiter J, Just I, Leutner M. et al.
Combined exenatide and dapagliflozin has no additive effects on reduction of hepatocellular lipids despite better glycaemic control in patients with type 2 diabetes mellitus treated with metformin: EXENDA, a 24-week, prospective, randomized, placebo-controlled pilot trial.
Diabetes Obes Metab 2021;
23 (05) 1129-1139
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.